In this episode of From Bench to Fireside, host John Connolly, PhD, Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy (PICI), interviews Carl June, MD, Director of the PICI Center at the University of Pennsylvania. Known as "the Father of CAR T-cell therapy," Dr. June's groundbreaking work led to the first FDA-approved CAR T-cell therapy in 2017, revolutionizing precision medicine. Together, they explore the impact of the PICI Network in breaking barriers to accelerate patient-focused progress, the latest advances in CRISPR and CAR T-cell delivery shaping cellular therapy's future, and Dr. June’s reflections on his legacy, the next generation of scientists, and the importance of collaborative research.
--
From Bench to Fireside™ is a new podcast from the Parker Institute for Cancer Immunotherapy (PICI) that takes you from behind the lab bench to the frontiers of cancer research. Each episode features an interview with members of the PICI Network, pioneers in cancer immunotherapy and leaders at world-renowned cancer research institutions. Throughout the conversations, these experts weigh in on the potential of the human immune system to target and eradicate cancer cells, from the latest breakthroughs in immuno-oncology to their impact on patients. Along the way, they unpack the hurdles encountered and the opportunities that lie ahead.
Tune in to hear from scientific leaders who stand at the forefront of developing breakthrough immune therapies with the goal of turning all cancers into curable diseases. From Bench to Fireside™ is produced by the Parker Institute for Cancer Immunotherapy. Follow PICI on LinkedIn, X @parkerici or visit www.parkerici.org.
